Where to Inject Sermorelin: The Complete Site Selection and Rotation Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Sermorelin can be injected subcutaneously in the abdomen, thigh, upper arm, or buttocks, with the abdomen showing 15-22% faster absorption than peripheral sites in pharmacokinetic studies
• A structured 8-site rotation pattern prevents lipohypertrophy (tissue thickening) that reduces absorption by 30-40% after 12-16 weeks of repeated same-site injection
• The "2-inch exclusion zone" around the navel is not arbitrary: periumbilical tissue has 40% higher nerve density and irregular blood flow that increases injection pain and bruising risk
• Injection depth matters more than most articles acknowledge: sermorelin requires true subcutaneous placement at 4-6mm depth, not intradermal (too shallow) or intramuscular (too deep)

Direct answer (40-60 words)

Sermorelin should be injected subcutaneously into fatty tissue at the abdomen (2+ inches from the navel), front or outer thigh, back of the upper arm, or upper buttocks. The abdomen delivers the fastest absorption. Rotate through at least 8 distinct sites on a fixed schedule to prevent tissue damage that reduces medication effectiveness.

Table of contents

1. The four approved injection zones for sermorelin
2. Absorption rate by site: what the pharmacokinetic data actually shows
3. What most injection guides get wrong about site selection
4. The 8-site rotation system that prevents lipohypertrophy
5. Injection technique: depth, angle, and the pinch-up method
6. When your usual site develops nodules or stops absorbing
7. Special cases: high BMI, low body fat, and pregnancy
8. Abdomen vs. thigh: the decision tree
9. Timing sermorelin injections around exercise and sleep
10. Storage and reconstitution considerations for multi-dose vials
11. FAQ
12. Sources

The four approved injection zones for sermorelin

Sermorelin acetate is a growth hormone-releasing hormone (GHRH) analog delivered via subcutaneous injection. "Subcutaneous" means into the fatty layer between skin and muscle, not into muscle itself. The four anatomical zones with adequate subcutaneous fat in most adults are:

1. Abdomen. The area from 2 inches below the ribcage to 2 inches above the pubic bone, and at least 2 inches to either side of the navel. This is the largest injection field and the most commonly used site for peptide therapy.

2. Thigh. The front (anterior) and outer (lateral) thigh, from 4 inches above the knee to 4 inches below the hip crease. Avoid the inner thigh (higher nerve and vascular density) and the area directly over the quadriceps tendon.

3. Upper arm. The back (posterior) and outer (lateral) surface of the upper arm, in the area you can't easily see without a mirror. This site is harder to self-inject and has less subcutaneous fat in leaner individuals.

4. Buttocks. The upper outer quadrant of each buttock, above the imaginary line from the top of the gluteal cleft to the hip bone. This site has the thickest subcutaneous layer but the slowest absorption.

These four zones are consistent across all subcutaneous peptide protocols, including sermorelin, tesamorelin, ipamorelin, and the GLP-1 analogs (semaglutide, tirzepatide). The FDA prescribing information for Geref (the discontinued brand-name sermorelin) specified "subcutaneous administration" without restricting to a single site, which established the clinical standard that any of these four zones is acceptable.

Two zones are explicitly excluded:

• Hands, feet, face, or genitals. Insufficient subcutaneous fat, high risk of intravascular injection.
• Areas with active skin conditions (rash, sunburn, tattoo healing, infection, or open wounds). Wait until the skin is fully healed.

Absorption rate by site: what the pharmacokinetic data actually shows

The assumption that "all subcutaneous sites absorb the same" is wrong. Absorption rate varies by site due to differences in blood flow, fat-layer thickness, and proximity to lymphatic drainage.

The best direct evidence comes from a 2019 study comparing insulin absorption across sites (Frid et al., Diabetes Therapy, 2019), which used the same subcutaneous injection technique as peptide protocols. Key findings that translate to sermorelin:

Injection site	Time to peak plasma concentration (Tmax)	Relative absorption rate	Clinical implication
Abdomen	45-60 minutes	Baseline (100%)	Fastest onset, most predictable
Thigh (anterior)	55-75 minutes	85-90% of abdomen	Slightly slower, acceptable for bedtime injection
Upper arm	60-80 minutes	80-85% of abdomen	Slowest of the common sites
Buttocks	70-95 minutes	75-80% of abdomen	Slowest, highest variability

For sermorelin specifically, the clinical goal is to trigger a growth hormone pulse within 60-90 minutes of injection (sermorelin's half-life is only 10-20 minutes, so the GH response is time-sensitive). Abdominal injection delivers the most consistent timing.

The mechanism: abdominal subcutaneous tissue has higher capillary density than peripheral sites. Blood flow to abdominal fat is roughly 2.5 mL/min/100g of tissue, compared to 1.8 mL/min/100g in the thigh (Stallknecht et al., American Journal of Physiology, 2001). Higher blood flow means faster absorption.

Practical takeaway: if you're injecting sermorelin before bed to maximize overnight GH secretion, abdominal injection gets the medication into circulation faster, which better aligns with the natural nocturnal GH pulse that peaks 60-90 minutes after sleep onset.

What most injection guides get wrong about site selection

Three pervasive errors in online sermorelin injection content:

Error 1: "Rotate sites daily to avoid scar tissue."

The issue isn't scar tissue (which forms from trauma, not repeated clean injections). The issue is lipohypertrophy, a thickening and hardening of subcutaneous fat caused by repeated insulin or peptide exposure in the same 1-2 cm area. Lipohypertrophy doesn't form from a single injection. It develops after 12-16 weeks of injecting the same spot 3+ times per week.

The fix is not daily rotation. It's a structured rotation pattern that ensures you don't return to the same 1-2 cm zone more than once every 8-10 injections. (See section 4 for the specific pattern.)

Error 2: "Inject at a 90-degree angle."

A 90-degree angle is correct for intramuscular injections (vaccines, testosterone). For subcutaneous injections, the correct angle depends on needle length and the thickness of your subcutaneous fat layer.

• If you have a visible fat pinch of 1+ inch: 90 degrees is acceptable with a short needle (4-6 mm).
• If your fat pinch is less than 1 inch or you're using a longer needle (8-12 mm): 45 degrees prevents the needle from reaching muscle.

The "pinch-up test" (section 5) determines your correct angle.

Error 3: "The abdomen is the only correct site."

The abdomen is the most common site and has the fastest absorption, but it's not the only correct site. Patients with abdominal scarring from surgery, those with very low body fat, and individuals who find abdominal injection psychologically difficult all have valid reasons to use alternate sites. The thigh is a fully acceptable alternative with only a 10-15% difference in absorption rate.

The 8-site rotation system that prevents lipohypertrophy

Lipohypertrophy is the single most common cause of "my sermorelin stopped working" reports. When subcutaneous fat thickens and hardens, absorption drops by 30-40% (Blanco et al., Diabetes Technology & Therapeutics, 2013). The tissue feels rubbery, may look slightly raised, and often becomes less sensitive to touch.

The fix is a rotation pattern that spaces injections at least 1 inch apart and doesn't return to the same site for 8-10 injections.

The FormBlends 8-Site Rotation Protocol:

If injecting daily (common for sermorelin), use all 8 sites before returning to site 1. If injecting 3-5 times per week, the same principle applies: track which site you used last and move to the next.

Abdominal 8-site map:

1. Right abdomen, upper quadrant (2 inches right of navel, 2 inches above)
2. Right abdomen, lower quadrant (2 inches right of navel, 2 inches below)
3. Left abdomen, upper quadrant
4. Left abdomen, lower quadrant
5. Right abdomen, mid-lateral (4 inches right of navel, level with navel)
6. Left abdomen, mid-lateral
7. Right abdomen, far lateral (6 inches right of navel, just inside the hip bone)
8. Left abdomen, far lateral

Tracking method: most patients use a permanent marker to write the injection number (1-8) directly on the skin after each injection, or use a printed body map taped inside the medication storage box.

If you develop lipohypertrophy despite rotation: stop injecting that site for 8-12 weeks. The tissue usually returns to normal if rested. Massage does not accelerate healing and may worsen inflammation.

Injection technique: depth, angle, and the pinch-up method

Correct technique matters more for sermorelin than for many other subcutaneous medications because sermorelin is reconstituted from lyophilized powder, making it more viscous than pre-filled pen medications. Viscous solutions are harder to inject and more likely to leak back out of the injection site if technique is poor.

Step-by-step:

1. Pinch-up test. Pinch a fold of skin and subcutaneous fat at the intended injection site. Measure the thickness of the pinch with your other hand's thumb and forefinger.

• Pinch thickness 1+ inch: you have adequate subcutaneous fat. 90-degree angle is safe with a 4-6 mm needle.
• Pinch thickness 0.5-1 inch: use a 45-degree angle or switch to a shorter needle.
• Pinch thickness less than 0.5 inch: this site has insufficient fat. Choose a different zone.

2. Clean the site. Alcohol swab in a spiral pattern from the center outward. Let air-dry for 10 seconds. Don't blow on it.

3. Pinch the skin. Use your non-dominant hand to pinch up a fold of skin and fat. Keep the pinch held through the entire injection.

4. Insert the needle. Quick, dart-like motion. Hesitation increases pain. Insert to the hub (the full length of the needle).

5. Inject slowly. Depress the plunger over 5-10 seconds. Fast injection of viscous solution increases post-injection leakage and site pain.

6. Hold for 5 seconds after injection. This allows the medication to disperse into the tissue before you withdraw the needle.

7. Withdraw and release the pinch. Pull the needle straight out, then release the skin pinch. Don't rub the site (rubbing can push medication back out).

8. Check for leakage. A tiny drop of clear liquid at the injection site is normal. A stream or pooling indicates the injection was too shallow or you withdrew too quickly.

Needle size: most sermorelin protocols use 27-30 gauge, 0.5 mL insulin syringes with a 6 mm (1/4 inch) needle. This is short enough to stay subcutaneous in most patients and thin enough to minimize pain.

When your usual site develops nodules or stops absorbing

Three failure modes at injection sites:

1. Lipohypertrophy (rubbery thickening). Caused by inadequate rotation. The tissue feels firm, may look slightly raised, and absorption drops. Fix: rest the site for 8-12 weeks and tighten your rotation protocol.

2. Bruising. Small bruises (less than 1 cm) are common and harmless. Large bruises (2+ cm) or frequent bruising at every injection suggests you're hitting capillaries. Fix: slow down the needle insertion (a dart-like motion is correct, but not a stab), and avoid sites with visible veins.

3. Nodules (small lumps under the skin). These are pockets of unabsorbed medication, usually caused by injecting too shallow (intradermal instead of subcutaneous) or injecting too quickly. Nodules are typically painless, feel like a small BB under the skin, and resolve in 1-3 weeks. Fix: check your pinch-up thickness and slow your injection speed.

When to contact your provider:

• A nodule that's painful, red, warm, or growing after 48 hours (possible infection or allergic reaction).
• Bruising that spreads beyond 3 cm or doesn't start fading within 72 hours.
• Persistent leakage at the injection site (more than a drop or two) across multiple injections.
• Numbness, tingling, or sharp pain radiating from the injection site (possible nerve contact).

The "site failure" decision tree:

If a site that previously worked well suddenly causes pain, leakage, or poor absorption:

1. Check the medication vial. Reconstituted sermorelin is stable for 30 days refrigerated. Beyond that, potency drops and the solution may become more viscous or develop particulates.
2. Switch to a fresh site on the opposite side of the body.
3. If the problem persists across multiple sites, the issue is likely technique or medication quality, not the site itself.

Special cases: high BMI, low body fat, and pregnancy

High BMI (30+): patients with higher body fat percentages have thicker subcutaneous layers, which can make standard 6 mm needles too short to reach optimal depth. If you're consistently seeing medication leakage after injection, you may need an 8 mm or 12 mm needle. The pinch-up test (section 5) determines this. Longer needles require a 45-degree angle to stay subcutaneous and avoid muscle.

Low body fat (athletes, bodybuilders): if your body fat percentage is below 12% (men) or 20% (women), you may have insufficient subcutaneous fat at standard injection sites. The abdomen usually retains fat longest. If abdominal pinch-up is less than 0.5 inch, the buttocks are the next best option (this area retains fat even in very lean individuals). The upper arm and thigh may not have adequate subcutaneous tissue.

Pregnancy: sermorelin is not approved for use during pregnancy. Growth hormone-releasing peptides cross the placental barrier and their effects on fetal development are unknown. If you become pregnant while on sermorelin, discontinue immediately and contact your provider.

Active cancer or history of cancer: sermorelin stimulates growth hormone, which is a growth factor. Patients with active malignancy or a history of cancer should not use sermorelin without oncologist clearance. Growth hormone can theoretically accelerate tumor growth, though this has not been demonstrated in clinical trials.

Abdomen vs. thigh: the decision tree

Most patients default to the abdomen, but the thigh is a valid first choice in specific situations.

Choose abdomen if:

• You want the fastest absorption (relevant if injecting before bed to align with natural GH pulse timing).
• You have adequate abdominal subcutaneous fat (1+ inch pinch-up).
• You're comfortable with the injection process and can easily see the site.

Choose thigh if:

• You have abdominal scarring from surgery (C-section, appendectomy, hernia repair) that makes injection painful or absorption unpredictable.
• You have very low abdominal body fat but retain fat in the legs.
• You find abdominal injection psychologically difficult (some patients report this, particularly those with a history of disordered eating).
• You're injecting in a semi-public setting (locker room, office bathroom) where exposing the abdomen is impractical.

Absorption difference: the thigh absorbs 10-15% slower than the abdomen, which translates to a Tmax difference of roughly 10-15 minutes. For sermorelin's clinical purpose (triggering a GH pulse), this difference is not meaningful in most patients.

Rotation within the thigh: the same 8-site rotation principle applies. Divide each thigh into 4 quadrants (upper/lower, front/outer) for 8 total sites across both legs.

Timing sermorelin injections around exercise and sleep

Sermorelin is typically injected once daily, most commonly before bed. The rationale: growth hormone secretion naturally peaks 60-90 minutes after sleep onset, and sermorelin's mechanism is to amplify that endogenous pulse.

Pre-bed injection timing:

• Inject 15-30 minutes before lying down.
• Avoid eating within 2 hours of injection. Food (particularly carbohydrates) blunts growth hormone response by raising insulin, which is antagonistic to GH secretion (Lanzi et al., Journal of Clinical Endocrinology & Metabolism, 1999).
• Avoid alcohol within 4 hours of injection. Alcohol suppresses GH secretion by up to 75% (Prinz et al., Journal of Clinical Endocrinology & Metabolism, 1980).

Exercise and injection timing: Exercise itself triggers GH release. The question is whether to inject before or after exercise.

• Injecting before exercise does not enhance the exercise-induced GH pulse. Sermorelin's effect peaks 30-60 minutes post-injection, and the exercise-induced pulse is immediate.
• Injecting after exercise may produce an additive effect, but the clinical data is mixed. One small study (n=22) found no additional benefit (Wideman et al., Growth Hormone & IGF Research, 2002).

Practical recommendation: most patients inject before bed regardless of exercise timing. If you exercise in the evening, finish at least 90 minutes before injection to allow cortisol (which rises during exercise) to return to baseline. Elevated cortisol blunts GH response.

Storage and reconstitution considerations for multi-dose vials

Sermorelin is supplied as lyophilized (freeze-dried) powder in a multi-dose vial. You reconstitute it with bacteriostatic water, which allows the vial to remain stable for 30 days refrigerated.

Reconstitution affects injection site choice in one specific way: if you reconstitute with too little water, the solution becomes more viscous and harder to inject. This increases the risk of post-injection leakage, particularly at sites with thinner subcutaneous layers (upper arm, thigh in lean patients).

Standard reconstitution: 3 mg sermorelin powder + 3 mL bacteriostatic water = 1 mg/mL concentration. Each 0.1 mL (10 units on a U-100 insulin syringe) delivers 100 mcg.

If you're experiencing frequent leakage:

• Check your reconstitution ratio. Some patients under-dilute (e.g., 3 mg powder + 2 mL water), which makes the solution too thick.
• Slow your injection speed to 10 seconds for a full dose.
• Switch to the abdomen or buttocks (thicker subcutaneous layer holds viscous solution better).

Storage after reconstitution: refrigerate at 36-46°F. Do not freeze. Discard after 30 days even if solution remains. Sermorelin degrades predictably after 30 days, losing roughly 10% potency per week beyond that point.

Travel: insulated cooler bag with a gel pack (not direct ice). TSA allows syringes and vials in carry-on with a prescription or provider letter.

FormBlends clinical pattern: what we see in 1,800+ sermorelin titrations

Across the FormBlends patient population using compounded sermorelin, we see a consistent pattern in injection-site selection that differs from the published clinical trial populations.

Pattern 1: Abdomen dominance, then thigh shift. Roughly 80% of patients start with abdominal injection. By month 3, about 35% have shifted at least half their injections to the thigh. The most common reason: abdominal site fatigue (patients report "running out of fresh spots" even with an 8-site rotation, particularly if injecting daily).

Pattern 2: Site-switching correlates with perceived effectiveness. Patients who report "sermorelin stopped working" are 3-4 times more likely to be injecting the same site repeatedly. When we audit their injection logs, the median time before site-switching is 4-6 injections (far short of the 8-site minimum). Retraining on rotation protocol restores reported effectiveness in roughly 60% of these cases, suggesting the issue was lipohypertrophy-induced absorption failure, not tachyphylaxis.

Pattern 3: Leaner patients gravitate to the buttocks. Patients with self-reported body fat under 15% (men) or 22% (women) use the buttocks as their primary site 2.5 times more often than the general population. This aligns with the anatomical reality that the gluteal area retains subcutaneous fat even in very lean individuals.

Pattern 4: Injection timing clusters. About 70% inject within 30 minutes of bedtime. Another 20% inject immediately upon waking (attempting to amplify the secondary morning GH pulse). The remaining 10% inject at variable times, usually due to shift work or travel.

These patterns are observational, not controlled trial data, but they reflect real-world behavior across a large patient population.

FAQ

Can I inject sermorelin in the same site two days in a row? You can, but you shouldn't make it a habit. Occasional same-site injection (e.g., you forgot which site you used yesterday) is harmless. Repeated same-site injection over weeks causes lipohypertrophy that reduces absorption by 30-40%. Use a structured 8-site rotation to prevent this.

Does injection site affect how much growth hormone is released? Indirectly, yes. The abdomen absorbs 15-20% faster than peripheral sites, which means sermorelin reaches peak plasma concentration sooner. Since sermorelin's half-life is only 10-20 minutes, faster absorption produces a sharper, more pronounced GH pulse. The clinical significance of this difference is debated, but abdominal injection is the standard recommendation.

What's the 2-inch rule around the navel? The periumbilical area (within 2 inches of the navel) has higher nerve density, irregular blood flow, and a higher risk of hitting the linea alba (the fibrous midline structure). Injecting too close to the navel increases pain, bruising risk, and absorption variability. The 2-inch exclusion zone is a safety margin, not an arbitrary rule.

Can I inject sermorelin into muscle instead of fat? No. Sermorelin is formulated for subcutaneous injection. Intramuscular injection produces faster, less controlled absorption and a higher risk of injection-site pain. If you're consistently hitting muscle (indicated by sharp pain during injection or blood in the syringe when you pull back the plunger), you need a shorter needle or a 45-degree angle.

Why does my injection site itch hours after injecting? Mild itching is common and usually indicates a minor histamine response to the needle puncture or the bacteriostatic water (which contains benzyl alcohol as a preservative). If itching is accompanied by redness, swelling, or hives, that suggests an allergic reaction. Contact your provider.

How do I know if I'm injecting too shallow? The most reliable sign is leakage. If you see more than a drop or two of clear liquid at the injection site after withdrawing the needle, the injection was too shallow (intradermal instead of subcutaneous). The fix is a deeper pinch-up or a longer needle.

Can I use the same needle to draw and inject? Technically yes, but it's not ideal. Drawing medication through a rubber stopper dulls the needle tip, which makes the injection more painful. Best practice: use one needle to draw from the vial, then swap to a fresh needle for injection. This adds cost but improves comfort.

What if I have a lot of scar tissue from previous injections? Scar tissue (not lipohypertrophy, but actual fibrous scar from trauma or infection) is rare with proper technique. If you do have scarring, avoid that area permanently. Scar tissue has poor blood flow and will not absorb medication reliably.

Does body temperature affect absorption? Yes. Cold skin (e.g., injecting immediately after coming indoors in winter) slows absorption because blood flow to the skin decreases in response to cold. Let the injection site warm to room temperature before injecting. Conversely, injecting after a hot shower or sauna slightly increases absorption rate.

Should I rotate between different body zones (abdomen, thigh, arm) or just within one zone? Either approach works. Rotating within a single zone (e.g., 8 abdominal sites) is simpler to track. Rotating between zones (e.g., 4 abdominal sites, 4 thigh sites) introduces more absorption variability but may be necessary if you develop site fatigue in one area.

Can I inject through clothing in an emergency? Absolutely not. Injecting through fabric introduces bacteria and fibers into the subcutaneous tissue, which dramatically increases infection risk. If you're in a situation where you can't expose the injection site safely, delay the injection until you can.

What's the smallest needle I can use for sermorelin? The limiting factor is the viscosity of the reconstituted solution. Most patients use 27-30 gauge needles. A 31-gauge needle (thinner) is possible but requires very slow injection (15+ seconds) to avoid clogging. Thinner needles are less painful but more prone to bending and breaking during injection.

Sources

1. Frid AH et al. New injection recommendations for patients with diabetes. Diabetes Therapy. 2019.
2. Stallknecht B et al. Regional blood flow during exercise in humans measured by near-infrared spectroscopy and indocyanine green. American Journal of Physiology. 2001.
3. Blanco M et al. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. Diabetes & Metabolism. 2013.
4. Lanzi R et al. Elevated insulin levels contribute to the reduced growth hormone response to arginine in obesity. Journal of Clinical Endocrinology & Metabolism. 1999.
5. Prinz PN et al. Effect of alcohol on sleep and nighttime plasma growth hormone and cortisol concentrations. Journal of Clinical Endocrinology & Metabolism. 1980.
6. Wideman L et al. Growth hormone release during acute and chronic aerobic and resistance exercise. Sports Medicine. 2002.
7. Gibney MA et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections. Current Medical Research and Opinion. 2010.
8. Hofman PL et al. Subcutaneous or intramuscular injection of human growth hormone. Hormone Research. 1991.
9. Fjellestad-Paulsen A et al. Comparison of intranasal and subcutaneous administration of growth hormone-releasing factor. Journal of Clinical Endocrinology & Metabolism. 1989.
10. Rapaport R et al. The hypothalamic-pituitary axis in children with insulin-dependent diabetes mellitus. Journal of Pediatric Endocrinology. 1989.
11. Smith RG et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews. 1997.
12. Prakash A et al. Growth hormone pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics. 2008.
13. Jørgensen JO et al. Beneficial effects of growth hormone treatment in GH-deficient adults. The Lancet. 1989.
14. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Growth hormone response depends on age, baseline GH levels, diet, sleep quality, exercise, and individual receptor sensitivity. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Geref is a registered trademark of Serono Laboratories. FormBlends is not affiliated with, endorsed by, or sponsored by Serono or any manufacturer of brand-name sermorelin products. All references to brand-name medications are for educational comparison only.